
    
      The hypothesis of this study considers high levels of IL-18 during active Adult-onset still's
      disease as the therapeutic target. Treatment with IL-18BP will permit to inhibit the
      pro-inflammatory cascade triggered by IL-18 and may help to manage the different components
      of the disease.

      This study is an open label, dose-finding study involving multiple centers in Europe. Two
      dose cohorts (80mg and 160mg) were treated during twelve weeks and followed-up for four more
      weeks.
    
  